SUZHOU, China, October 19, 2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to present three posters highlighting study results from ongoing trials related to Osemitamab (TST001) at the 2023 European Society of Medical Oncology (ESMO) Congress including updated efficacy and PK/PD analysis data from the phase 2 study of Osemitamab (TST001)/CAPOX in CLDN18.2 positive first line G/GEJC as well as preclinical data on the combination study of Osemitamab (TST001) with PD1 inhibitor.

A brief summary of the presentations is as follows:

Title: First-line Osemitamab (TST001) plus Capecitabine and Oxaliplatin (CAPOX) for Advanced G/GE Cancer with CLDN18.2 Positive - Update Efficacy data from Study TranStar102-Cohort C

Abstract#: 1524P

Type: Abstract

Category: Oesophagogastric cancer

First Author: Prof. Lin Shen, Beijing Cancer Hospital

Date: October 21-23, 2023 (CEST)

Title: Osemitamab (TST001)，an ADCC Enhanced Humanized Anti-CLDN18.2 mAb, Demonstrated lmproved Efficacy in Combination with anti-PD-L1/PD-1mAb and Oxaliplatin/5-FU in Preclinical Tumor Models

Abstract#: 1560P

Type: Abstract

Category: Oesophagogastric cancer

First Author: Dr. Xueming Qian, Suzhou Transcenta Therapeutics Co., Ltd.

Date: October 23, 2023 (CEST)

Title: Pharmacokinetics, Pharmacodynamics and Exposure Response Analyses of Osemitamab (TST001) in Patients with Locally Advanced or Metastatic Solid Tumors

Abstract#: 1556P

Type: Abstract

Category: Oesophagogastric cancer

First Author: Prof. Lin Shen, Beijing Cancer Hospital

Date: October 23, 2023 (CEST)

The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

ESMO 2023 will disseminate the latest cutting-edge data, provide high quality education and unparalleled networking opportunities for oncologists and other stakeholders from all around the world. This year, the ESMO Congress will take place on October 20 to October 24, local time, in Madrid, Spain.